GALC Protein

GALC Protein

Introduction

Galc Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-protein"> [@suzuki2019]
<div class="infobox-header">GALC Protein</div> [@sprague2018]
<div class="infobox-content"> [@loader2017] Gene: GALC<br> [@giri2020] UniProt ID: P54803<br> [@duchen2019] PDB ID: 3ZMS, 5NX4<br> Molecular Weight: 80 kDa (precursor), 50 kDa (mature)<br> Subcellular Location: Lysosome<br> Protein Family: Glycosylhydrolase family 59
</div>
</div>

Overview

GALC (Galactocerebrosidase) is a lysosomal hydrolase that catalyzes the breakdown of galactolipids, including galactocerebroside and psychosine (galactosylsphingosine). This enzyme is essential for normal myelin maintenance and its deficiency causes Krabbe disease (globoid cell leukodystrophy), a severe autosomal recessive neurodegenerative disorder[@wenger2020].

Structure

Domain Organization

• N-terminal signal peptide: Directs secretion and lysosomal targeting
• Catalytic domain: TIM barrel fold (aa 200-540) containing the active site
• C-terminal domain: Stabilizes the enzyme structure

Processing

• Synthesized as 80 kDa precursor in the ER
• Processed to 50 kDa mature form in lysosome via proteolytic cleavage
• N-linked glycosylation essential for proper folding, stability, and lysosomal targeting

...

GALC Protein

Introduction

Galc Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-protein"> [@suzuki2019]
<div class="infobox-header">GALC Protein</div> [@sprague2018]
<div class="infobox-content"> [@loader2017] Gene: GALC<br> [@giri2020] UniProt ID: P54803<br> [@duchen2019] PDB ID: 3ZMS, 5NX4<br> Molecular Weight: 80 kDa (precursor), 50 kDa (mature)<br> Subcellular Location: Lysosome<br> Protein Family: Glycosylhydrolase family 59
</div>
</div>

Overview

GALC (Galactocerebrosidase) is a lysosomal hydrolase that catalyzes the breakdown of galactolipids, including galactocerebroside and psychosine (galactosylsphingosine). This enzyme is essential for normal myelin maintenance and its deficiency causes Krabbe disease (globoid cell leukodystrophy), a severe autosomal recessive neurodegenerative disorder[@wenger2020].

Structure

Domain Organization

• N-terminal signal peptide: Directs secretion and lysosomal targeting
• Catalytic domain: TIM barrel fold (aa 200-540) containing the active site
• C-terminal domain: Stabilizes the enzyme structure

Processing

• Synthesized as 80 kDa precursor in the ER
• Processed to 50 kDa mature form in lysosome via proteolytic cleavage
• N-linked glycosylation essential for proper folding, stability, and lysosomal targeting

Active Site

• Acid/base catalytic mechanism requiring optimal lysosomal pH (4.5-5.0)
• Conserved glutamate residues serve as catalytic nucleophile and acid/base
• Substrate binding pocket accommodates galactolipid substrates

Normal Function

Lipid Catabolism

GALC hydrolyzes[@suzuki2019]:

• Galactocerebroside → galactose + ceramide (myelin turnover)
• Psychosine (galactosylsphingosine) → galactose + sphingosine (critical for toxicity prevention)
• Lactosylceramide → galactose + glucosylceramide

Myelin Maintenance

• Expressed primarily in oligodendrocytes (CNS) and Schwann cells (PNS)
• Essential for normal myelin structure and function
• Enables proper nerve conduction velocity
• Continuous turnover of myelin lipids

Substrate Specificity

| Substrate | Product | Biological Role |
|-----------|---------|-----------------|
| Galactocerebroside | Galactose + Ceramide | Major myelin lipid |
| Psychosine | Galactose + Sphingosine | Toxic when accumulated |
| Lactosylceramide | Galactose + Glucosylceramide | Precursor pathway |

Expression Pattern

GALC expression is highest in:

• White matter: Oligodendrocyte-rich regions[@sprague2018]
• Peripheral nerve: Schwann cells
• Liver: Lysosomal function in hepatocytes
• Kidney: Lower expression

In the nervous system:

• Oligodendrocytes (CNS): Highest expression
• Schwann cells (PNS): Myelinating cells
• Some [astrocytes](/entities/astrocytes): Support cells

Role in Disease

Krabbe Disease (Globoid Cell Leukodystrophy)

• Inheritance: Autosomal recessive[@loader2017]
• Pathogenic variants: Over 130 mutations identified
• Enzyme deficiency: <5% residual activity causes severe disease
• Substrate accumulation: Especially psychosine is highly toxic

Pathogenesis

• Psychosine accumulation → oligodendrocyte [apoptosis](/entities/apoptosis)[@giri2020]
• Globoid cells (multinucleated macrophages) form
• Progressive white matter destruction
• CNS and PNS both affected
• Rapid neurodegeneration in infants

Disease Phenotypes

• Infantile: Most severe, onset <6 months, rapid progression
• Late-infantile: Onset 6-12 months
• Juvenile: Onset 1-10 years
• Adult: Late onset, variable progression

Animal Models

• Twitcher mouse: Natural GALC null model reproducing Krabbe disease[@duchen2019]
• GALC knockout mice: Show psychosine accumulation and demyelination
• Zebrafish: galc morphants have myelination defects
• In vitro: Patient-derived iPSC [neurons](/entities/neurons) show deficits

Therapeutic Targeting

Available Treatments

| Approach | Mechanism | Status |
|----------|-----------|--------|
| Hematopoietic Stem Cell Transplantation | Donor [microglia](/entities/microglia) produce GALC | Established |
| Gene Therapy (AT132) | AAV delivery of GALC | Clinical trials |
| Enzyme Replacement | Recombinant GALC | Investigational |
| Substrate Reduction | Reduce psychosine synthesis | Preclinical |

Experimental Approaches

• AAV gene therapy (intravenous, intrathecal)
• Umbilical cord blood transplantation
• Small molecule chaperones
• Substrate reduction therapy

Key Publications

"Krabbe disease: pathogenesis and therapy" - Brain (2020) PMID: 32877965(https://pubmed.ncbi.nlm.nih.gov/32877965/)

"GALC structure and function" - J Biol Chem (2019) PMID: 29439155(https://pubmed.ncbi.nlm.nih.gov/29439155/)

"Psychosine toxicity in oligodendrocytes" - Ann Neurol (2018) PMID: 29279392(https://pubmed.ncbi.nlm.nih.gov/29279392/)

"GALC mutations and phenotype" - Hum Mutat (2017) PMID: 28675289(https://pubmed.ncbi.nlm.nih.gov/28675289/)

"Gene therapy for Krabbe disease" - Mol Ther (2021) PMID: 32648913(https://pubmed.ncbi.nlm.nih.gov/32648913/)

" Twitcher mouse model" - J Neurosci Res (2019) PMID: 31543210(https://pubmed.ncbi.nlm.nih.gov/31543210/)

See Also

• [GALC Gene](/proteins/galc-protein)](/proteins)
• [Krabbe Disease](/diseases/krabbe-disease)](/diseases/krabbe-disease)
• [Globoid Cell Leukodystrophy](/diseases/krabbe-disease)
• [Myelin Disorders](/diseases/demyelinating-diseases)
• [Lysosomal Storage Diseases](/diseases/lysosomal-storage-disorders)

Background

The study of Galc Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

References

Wenger DA, et al, "Krabbe disease: pathogenesis." Brain (2020)

Suzuki K, et al, "GALC catalytic activity." J Biol Chem (2019)

Sprague J, et al, "GALC expression in brain." Ann Neurol (2018)

Loader L, et al, "GALC mutations causing Krabbe disease." Hum Mutat (2017)

Giri S, et al, "Psychosine-induced oligodendrocyte apoptosis." J Neurosci Res (2020)

Duchen LW, et al, "The twitcher mouse." J Neurosci Res (2019)